The study will take place at HMar Research Institute led by Dr Rafael de la Torre Fornell and Dr Ana Aldea as principal investigators 👇🏼

We was recently granted a participatory loan for €600,000 from the Spanish National Innovation Company (enisa).

CONNECTA Therapeutics begins administration of #CTH120 to the first healthy volunteers in Phase I #ClinicalTrial at Hospital del Mar - HMar Research Institute in Barcelona. Learn more on our website: bit.ly/3rx8qW1 #FragileXSyndrome #FragileX #RareDiseases #CNS #OrphanDrug

Every year on July 22, World Fragile X Day is celebrated around the world to raise awareness on Fragile X Syndrome and to contribute to the cause by reading up on the condition. Show your support by learning more about #FragileX: worldfragilexday.com #FXS #health

Thanks to the Barcelona Centre Universitari for including Connecta Therapeutics, based at Parc Científic de Barcelona, in the latest Talent Guide 23/24 to facilitate the arrival of international students in #Barcelona. Amazing! Download: bcu.cat/wp-content/upl… #science #biotech #FXS #FragileX

🔴 ÚLTIMA HORA | El @CPAOlot, campió del món per catorzena vegada ➡ Les patinadores olotines han guanyat aquest diumenge el títol mundial a Colòmbia #Garrotxa #Olot naciodigital.cat/garrotxa/notic…

Today is International Fragile X Awareness Day. At CONNECTA Therapeutics we are committed to raising awarenesss of #fragilexsyndrome #internationalfragilexawarenessday

Today, on World Fragile X Day, we stand in solidarity with the families and individuals affected by this genetic condition. At CONNECTA Therapeutics, we are dedicated to advancing research and developing innovative treatments to improve the lives of those with #FragileX syndrome.

Fragile X syndrome (#FXS), a leading cause of inherited intellectual disability, presents unique challenges that require our collective effort to address. Our team is committed to pushing the boundaries of science to bring hope and solutions to the Fragile X community.

As we continue our journey towards developing a therapy, we are inspired by the resilience and strength of those living with FXS. We extend our heartfelt thanks to the organizations, researchers, and families whose support and collaboration are crucial to this important mission.

Let's unite to raise awareness, support research, and advocate for a brighter future. Together we can make a difference. youtu.be/YavDg8PMlxs?si…

El proper 21 i 22 de febrer tenim el plaer de participar a les IV Jornades d’Actualització de la Síndrome X Fràgil per a professionals i families, organitzades per Associació Catalana Síndrome X Fràgil i Institut d'Investigació i Innovació Parc Taulí Francis Sullivan Per a més informació: xfragil.cat/ca/iv-jornades…

Today, February 28, is World #RareDiseasesDay, a special day to raise awareness on the extraordinary strength and resilience of 300 M people worldwide living with rare diseases. Video: youtu.be/fIvqxQPjisI

CONNECTA Therapeutics announces positive results from Phase I clinical trial of neurodevelopmental disorders drug candidate CTH120: bit.ly/3QN8XMM A randomised, double-blind and placebo-controlled study that recruited 76 healthy adults at HMar Research Institute in Barcelona👇🏼

🚀Big step for CONNECTA Therapeutics ! Our lead candidate #CTH120 moves to Phase II pediatric trials, co-funded by the EU with a €2.5M European Innovation Council Accelerator grant. Read more about our aim to deliver the first disease-modifying therapy for #FragileXSyndrome👇 bit.ly/4pft6Ly #EUeic

🚀Un gran paso para CONNECTA Therapeutics! #CTH120 avanza a ensayos clínicos pediátricos de Fase II, cofinanciado por la UE con 2,5M€ bajo el programa European Innovation Council Accelerator. Más información sobre nuestra primera terapia modificadora para #SindromeXFragil👇 bit.ly/4pft6Ly #EUeic

🚀Un gran pas per CONNECTA Therapeutics! #CTH120 avança cap a assajos clínics pediàtrics de Fase II, cofinançat per la UE amb 2,5M€ sota el programa European Innovation Council Accelerator. Per més informació sobre la nostra primera teràpia modificadora per #SindromeXFragil👇 bit.ly/4pft6Ly #EUeic

🧠 October is #ADHDAwarenessMonth! At CONNECTA Therapeutics, we’re developing #neuroplasticity modulators that aim to go beyond symptoms and target underlying pathways in #ADHD and other #CNS disorders. 🙏 Thanks ADHDAwarenessMonth for shining a light on the many faces of ADHD!

💜 October is #RettSyndromeAwareness Month! At CONNECTA Therapeutics, we stand with the global Rett community and are dedicated to advancing science that tackles the root causes of #RareDisease. #RettSyndromeAwareness #NeurodevelopmentalDisorders

💜 It’s #ChildNeurologyAwarenessDay! CONNECTA Therapeutics is advancing #CTH120, a first-in-class therapy now starting the pediatric development for Fragile X Syndrome (#FXS) supported by the EU-funded #FRAXCURE project. #ChildNeurology #RareDisease